Key result
Emerging Lp(a)-targeted therapies have the potential to provide the first pharmacological option to slow disease progression in high-risk patients with aortic valve stenosis.
This review explores lipoprotein(a)'s role in aortic valve stenosis, highlighting emerging therapeutic options for high-risk individuals.
Aortic valve stenosis (AVS) is the most common valvular disease in developed countries, and no pharmacological therapy is currently available. Increasing evidence identifies lipoprotein(a) [Lp(a)] as a causal factor linking lipid metabolism, inflammation, and valve calcification. Lp(a) levels are largely genetically determined and remain stable throughout life, making them a potential therapeutic target. This review summarizes the current evidence on Lp(a) and AVS pathophysiology, the diagnostic and prognostic role of Lp(a), and the therapeutic potential of Lp(a)-lowering agents. Emerging Lp(a)-targeted therapies, including antisense oligonucleotides and siRNA-based agents, could reshape AVS management by providing the first pharmacological option to slow disease progression in selected high-risk patients.
No takes yet. Share an insight, caveat, or question.
Agnello et al. (2025) studied this question. Emerging Lp(a)-targeted therapies have the potential to provide the first pharmacological option to slow disease progression in high-risk patients with aortic valve stenosis.